JOHN A. MORAN EYE CENTER ALAN S. CRANDALL CENTER FOR GLAUCOMA INNOVATION: OVERVIEW
Nearly 80 million people are living with glaucoma, a blinding disease that will rob them of their eyesight. That number is projected to rise to 112 million people by 2040.
PRESSURE
DR AINAGE SYSTEM (TR A B E C U L A R MESHWORK)
FLUID ( A Q U E O U S H U M O R)
WHAT IS GLAUCOMA? A disease that damages the optic nerve, which carries visual information to the brain. It usually occurs when fluid inside the eye does not drain properly, causing an increase in pressure.
DA M AGE TO OPTIC NERVE
Directed by Iqbal Ike K. Ahmed, MD, FRCSC, the Crandall Center is creating new hope for people with glaucoma. Its four initiatives leverage unique resources at the John A. Moran Eye Center.
Glaucoma Therapeutics
Translational Research
NeuroprotectionBased Therapies
Conducting research to assist companies in developing safe and effective diagnostics and therapeutics.
Understanding the biology and genetics of glaucoma to develop new treatments.
Developing new therapies to protect, restore, or regenerate the optic nerve.
Global Care Finding better ways to diagnose glaucoma and inexpensive yet effective ways to treat it in low-resource nations.
CALL 801-585-9700 OR VISIT CRANDALLCENTER.ORG TO LEARN HOW YOU CAN SUPPORT NEW TREATMENTS FOR GLAUCOMA OR DONATE TO THE CENTER.
